Japan cuts device technology reimbursement by 5%
This article was originally published in Clinica
The Japanese Ministry of Health and Welfare has cut the reimbursement price for procedures involving medical technology by an average of 5%.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.